For the quarter ending 2025-06-30, VYNE had $2,121K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-06-30 |
|---|---|
| Net loss | -14,366 |
| Unrealized losses on cash equivalents | 0 |
| Stock-based compensation | 1,292 |
| Trade receivables, prepaid expenses and other assets and operating lease right-of-use assets | -306 |
| Operating lease liabilities | -74 |
| Trade payables, accrued expenses, employee related obligations and other long-term liabilities | -8,896 |
| Depreciation | 12 |
| Amortization of premium or discount on marketable securities | -538 |
| Net cash used in operating activities | -22,264 |
| Proceeds from sale and maturity of marketable securities | 47,850 |
| Purchases of marketable securities | 23,344 |
| Net cash provided by investing activities | 24,506 |
| Withholdings from exercise of options and issuance of shares for stock-based compensation arrangements, net | -121 |
| Net cash used in financing activities | -121 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 2,121 |
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. (VYNE)